Application for Admission - TruSpine Technologies PLC

ANNOUNCEMENT OF APPLICATION FOR ADMISSION TO THE AQSE GROWTH MARKET

APPLICANT NAME:

TruSpine Technologies PLC

APPLICANT REGISTERED OFFICE, PRINCIPLE PLACE OF BUSINESS (IF DIFFERENT) AND TELEPHONE NUMBER:

Spectrum House, Af33 Beehive Ring Road, London Gatwick Airport, Gatwick, RH6 0LG

DIRECTORS AND PROPOSED DIRECTORS (IF APPLICABLE):

Ian Anthony Roberts (Chief Executive Officer)

Norman Alec Charles Lott (Chief Financial Officer)

Martin Charles Armstrong (Non-executive Chairman)

Tim Hugh David Evans (Non-executive Director)

Annabel Martha Schild (Non-executive Director)

APPLICANT SECTOR:

Medical Devices

DESCRIPTION OF THE APPLICANT AND ITS ACTIVITIES:

TruSpine is a medical device company in the spinal device market. The Company is developing disruptive technologies to for use in the spinal stabilisation market, commencing with the following three devices:

Cervi-LOK - for the cervical and upper thoracic spine

Faci-LOK - for the lumbar and lower thoracic spine, and

GRASP Laminoplasty - a treatment for decompression of the spinal cord.

These devices represent a potential paradigm shift potentially significant development in spinal fixation, by providing stabilisation while not altering the bony spinal anatomy by using of patients through the use of screws, staples or other devices which currently dominate the spinal market.

The Company is seeking to obtain regulatory clearance from the US Food and Drug Administration ("FDA") for its Cervi-LOK product in Q1 2021 and will subsequently seek clearance for Faci-LOK and GRASP Laminoplasty.

NAME OF AQSE EXCHANGE CORPORATE ADVISER:

Cairn Financial Advisers LLP

NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:

[] ordinary shares of £0.0001 each

SECURITIES IN PUBLIC HANDS AS A PERCENTAGE OF THE TOTAL NUMBER OF SECURITIES IN ISSUE (excluding securities held in treasury):

Approximately []%

SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT'S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION: